851437-35-9

Basic information

• Product Name: 4-(allyloxy)-3-bromobenzonitrile
• Synonyms: 4-(allyloxy)-3-bromobenzonitrile
• CAS NO: 851437-35-9
• Molecular Weight: 238.084
• Mol File: 851437-35-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(allyloxy)-3-bromobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(allyloxy)-3-bromobenzonitrile(851437-35-9)
• EPA Substance Registry System: 4-(allyloxy)-3-bromobenzonitrile(851437-35-9)

Safety Data

• Hazardous Substances Data: 851437-35-9(Hazardous Substances Data)

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 2315-86-8 3-bromo-4-hydroxybenzonitrile 
• 106-95-6 allyl bromide 

Downstream Products

• 1620293-66-4 tert-butyl ((5-((2-bromo-4-cyanophenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)carbamate 
• 1620291-49-7 N-((5-(((5-cyano-4'-fluoro-[1,1'-biphenyl]-2-yl)oxy)methyl)-4,5 dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide 
• 1620291-56-6 N-((5-((4-cyano-2-(1-methyl-1H-pyrazol-4-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide 
• 1620293-68-6 4-((3-(aminomethyl)-4,5-dihydroisoxazol-5-yl)methoxy)-3-bromobenzonitrile hydrochloride 
• 1620293-70-0 N-((5-((2-bromo-4-cyanophenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide 
• 1072073-77-8 3-allyl-5-bromo-4-hydroxybenzonitrile 
• 724746-23-0 4-(allyloxy)-3-bromobenzaldehyde 

Relevant articles and documents

UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF

Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

ALYKYLENE DERIVATIVE HAVING EDG RECEPTOR ANTAGONISM

PROBLEM TO BE SOLVED: To provide novel compounds having EDG (endothelial differentiation gene) receptor antagonism which are useful as active components of drugs for preventing and/or treating inflammatory diseases or the like. SOLUTION: The compounds are represented by formula (I) (wherein R1 is hydrogen or an alkyl group; R2 is hydrogen present at any substitutable position on ring C or a substituent such as a hydroxy group, a carboxy group, and a nitro group; R3 is hydrogen present at any substitutable position on ring D or a substitutent such as a hydroxy group and an aralkyloxy group; X is an alkylamino group, an amino group or the like; Y is a carboxy group, a sulfo group or a phosphono group; Z is oxygen, sulfur or the like; a ring represented by A is a 5- or 6-membered saturated or unsaturated hydrocarbon ring; and a ring represented by B is a 4- or 7-membered saturated or unsaturated hydrocarbon ring containing one -C=C- as a partial structure shown in the above formula) and include their salts and their esters.